Eli Lilly's Growing Drug Portfolio Boosts Sales Beyond GLP-1

Written by Emily J. Thompson, Senior Investment Analyst

ADVM%

LLY+0.53%

ABBV-1.11%

Source: NASDAQ.COM

Updated: Nov 20 2025

0mins

Source: NASDAQ.COM

Eli Lilly's Stock Performance: Eli Lilly's stock reached over $1000 per share for the first time, driven by the success of its GLP-1 drugs, Mounjaro and Zepbound, and is approaching a $1 trillion market cap.
New Drug Approvals and Revenue Growth: The company has gained approvals for several new drugs, including Omvoh and Jaypirca, contributing significantly to revenue growth, with expectations for continued sales increases from these products in 2026.
M&A Strategy for Long-Term Growth: To diversify its portfolio beyond GLP-1 drugs, Lilly is pursuing mergers and acquisitions, including the recent agreement to acquire Adverum Biotechnologies, which will enhance its pipeline with gene therapies.
Competitive Landscape and Valuation: While Lilly's stock has outperformed the industry, it is considered expensive based on its price/earnings ratio, and analysts have raised earnings estimates for 2025 and 2026, indicating positive market sentiment.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Eli Lilly's Growing Drug Portfolio Boosts Sales Beyond GLP-1

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Trump Denies Considering JPMorgan's Dimon for Fed Chair Position

General Motors Increases Dividend by 25% and Launches $6 Billion Buyback Program

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch